About Fate Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://fatetherapeutics.com/
Frequently Asked Questions
What is the 52-week range for FATE?
The 52-week high is $3.23 and the 52-week low is $0.95.
What is the P/E ratio for FATE?
The P/E ratio data is currently unavailable.
What is the dividend yield for FATE?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -65.08%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1941.09%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.55.
Analyst Recommendation Trends
Wall Street analyst consensus for FATE over the last few months:
Latest FATE News
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on October 1, 2026, the Company granted (i) non-qualified stock options to one newly-hired non-executive employee to purchase a total of 62,900 shares of the Company’s common stock
Fate Therapeutics to Participate in Upcoming Fourth Quarter 2026 Conferences
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in the following investor conferences in the fourth quarter of 2026. 2026 Jefferies Global Healthcare Conference Location: London, UK Date: November 16th
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect
Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus Nephritis CLIN2 Grant is a highly competitive award from CIRM to fund advancing clinical trials for stem cell and gene therapies that have the potential to provide transformative benefits to patients and the healthcare system SAN DIEGO, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical c
Fate Therapeutics Receives $15M CIRM Grant To Advance Phase 2 FT819 Trial In Lupus Nephritis
$15.0 Million Award to Support Advancement of RECLAIM-LN, a Phase 2 Potentially Registrational Trial of FT819 Off-the-Shelf CAR T-Cell Therapy in Lupus NephritisCLIN2 Grant is a highly competitive award from CIRM to
Fate Therapeutics Selected for Four Presentations Highlighting its Off-the-Shelf CAR T-Cell Portfolio in Autoimmune Disease at ACR Convergence 2026
SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected for presentation at the American College of Rheumatology (ACR) Convergence 2026, being held November 6-1
Fate Therapeutics Says Four Abstracts From Off-The-Shelf CAR T-Cell Programs Selected For Presentation At ACR Convergence 2026
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819, and pre-clinical data from its off-the-shelf anti-CD19 and CD38 CAR T-cell product candidate FT839 wil
Fate Therapeutics To Present Clinical Data From Off-The-Shelf Anti-CD19 CAR T-Cell Product Candidate FT819, And Pre-Clinical Data From Anti-CD19 And CD38 CAR T-Cell Product Candidate FT839 At CCR – West Meeting
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-04 | TAHL CINDY | -38,800 | $2.4589 | $95,405 |
| 2026-08-04 | Valamehr Bahram | -43,947 | $2.4598 | $108,101 |
| 2026-06-12 | Xu Yuan | +87,900 | - | - |
| 2026-06-12 | Jooss Karin | +87,900 | - | - |
| 2026-06-12 | Agarwal Shefali | +87,900 | - | - |
| 2026-06-12 | ABERNETHY MATT | +87,900 | - | - |
| 2026-06-12 | Hamill Laura | +175,800 | - | - |
| 2026-06-12 | Lee Michael Stewart | +87,900 | - | - |
| 2026-06-12 | Redmile Group, LLC | +87,900 | - | - |
| 2026-06-12 | EPSTEIN ROBERT S | +87,900 | - | - |
| 2026-06-12 | RASTETTER WILLIAM H | +87,900 | - | - |
| 2026-05-20 | TAHL CINDY | -25,590 | $1.879 | $48,084 |
| 2026-05-20 | Valamehr Bahram | -28,946 | $1.8822 | $54,482 |
| 2026-05-06 | TAHL CINDY | -44,444 | - | - |
| 2026-05-06 | TAHL CINDY | -122,220 | - | - |
| 2026-05-06 | TAHL CINDY | +44,444 | $1.05 | $46,666 |
| 2026-05-06 | TAHL CINDY | +122,220 | $1.32 | $161,330 |
| 2026-05-05 | EPSTEIN ROBERT S | +25,000 | - | - |
| 2026-05-05 | EPSTEIN ROBERT S | +25,000 | $1.69 | $42,250 |
| 2026-05-05 | RASTETTER WILLIAM H | +25,000 | - | - |
| 2026-05-05 | RASTETTER WILLIAM H | +25,000 | $1.69 | $42,250 |
| 2026-04-20 | Redmile Group, LLC | +266,280 | - | - |
| 2026-04-20 | Redmile Group, LLC | -266,280 | - | - |
| 2026-04-20 | Redmile Group, LLC | +162,013 | - | - |
| 2026-04-20 | Redmile Group, LLC | -162,013 | - | - |
| 2026-04-20 | Redmile Group, LLC | +266,280 | - | - |
| 2026-04-20 | Redmile Group, LLC | -266,280 | - | - |
| 2026-04-20 | Redmile Group, LLC | +3,691,324 | - | - |
| 2026-04-20 | Redmile Group, LLC | -3,691,324 | - | - |
| 2026-04-20 | Redmile Group, LLC | +8,977,624 | - | - |
| 2026-04-20 | Redmile Group, LLC | -8,977,624 | - | - |
| 2026-01-15 | TAHL CINDY | +400,000 | - | - |
| 2026-01-15 | TAHL CINDY | +100,000 | - | - |
| 2026-01-15 | Adawi Kamal | +75,000 | - | - |
| 2026-01-15 | Adawi Kamal | +25,000 | - | - |
| 2026-01-15 | Valamehr Bahram | +1,300,000 | - | - |
| 2026-01-15 | Valamehr Bahram | +335,000 | - | - |
| 2026-01-09 | TAHL CINDY | -10,589 | $1.0648 | $11,275 |
| 2026-01-09 | Valamehr Bahram | -5,190 | $1.0708 | $5,557 |
| 2025-10-20 | Adawi Kamal | +375,000 | - | - |
| 2025-10-20 | Adawi Kamal | +75,000 | - | - |